INSYS Therapeutics Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.0M
Doctors Paid
6,122
Transactions
18,902
2018 Total
$3.7M
Payment Breakdown by Category
Research$10.3M (78.7%)
Consulting$867,248 (6.7%)
Food & Beverage$334,136 (2.6%)
Travel$269,546 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.3M | 781 | 78.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 334 | 10.0% |
| Consulting Fee | $867,248 | 288 | 6.7% |
| Food and Beverage | $334,136 | 17,133 | 2.6% |
| Travel and Lodging | $269,546 | 339 | 2.1% |
| Education | $179.61 | 27 | 0.0% |
Payments by Type
Research
$10.3M
781 transactions
General
$2.8M
18,121 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain | $2.2M | 0 | 10 |
| A Phase 1, Open-Label, Randomized, Multiple-Day, Multiple-Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Buprenorphine Sublingual Spray, Buprenorphine Sublingual Tablet, and Buprenex Intravenous Injection in Healthy Volunteers | $1.1M | 0 | 4 |
| A Phase 1, Proof-of-Concept, Single-Dose, Open-Label, 5?Treatment, Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and EpiPen (0.30 mg) Intramuscular Injection in Healthy Adults with Seasonal Allergies | $837,930 | 0 | 4 |
| Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder | $750,394 | 0 | 318 |
| A Phase 1, OpenLabel, Randomized, Parallel Group, Comparative Bioavailability Study of Buprenorphine Sublingual Spray, Buprenorphine Sublingual Tablet, and Buprenex Intravenous Injection in Healthy Volunteers | $693,798 | 0 | 4 |
| A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain | $651,014 | 0 | 10 |
| Cannabidiol Treatment in Patient with early psychosis | $446,812 | 0 | 11 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | $425,715 | 0 | 70 |
| A Phase 1, Proof-of-Concept, Single-Dose, Open-Label, Two-Treatment, Crossover, Comparative Bioavailability Study of Dronabinol Inhalation Aerosol (0.35 mg) and Marinol Capsules (5 mg) in Healthy Adult Volunteers under Fasted Conditions | $340,508 | 0 | 4 |
| A Pilot, Single-Dose, Two-Period, Two-Treatment, Two-Way Crossover Comparative Bioavailability Study of Fexofenadine Hydrochloride Softgel Capsule, 180 mg and Allegra Tablet, 180 mg, under Fasted Conditions | $328,899 | 0 | 3 |
| A Phase 1, Open-Label, Crossover, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Buprenorphine-Naloxone Sublingual Tablet in Healthy Volunteers | $311,674 | 0 | 3 |
| A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailability Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intravenous and Intramuscular Injection in Healthy Volunteers | $287,808 | 0 | 4 |
| A Phase 1, Open-Label, Randomized, Single-Dose, Four-Treatment, Four-Sequence, Four-Period, Four-Way crossover Food Effect Study of Multiple Formulations of Cannabidiol Oral Solution in Healthy Subjects | $229,239 | 0 | 4 |
| A Phase 1, Open-Label, Crossover, Comparative Bioavailability Study of Two Formulations of Fentanyl Sublingual Spray in Healthy Volunteers | $223,043 | 0 | 5 |
| A Phase 1, Open-Label, Single-Dose, Proof-of-Concept, Two-Way Crossover, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Buprenorphine-Naloxone Sublingual Tablet in Healthy Volunteers under Fasted Conditions | $176,180 | 0 | 3 |
| Cannabidiol | $171,239 | 0 | 81 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | $127,830 | 0 | 29 |
| A Phase 1, Single-Dose, Open-Label, Randomized, Crossover, Pharmacokinetic Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.3 mg EpiPen and 0.5 mg Adrenalin) in Healthy Adults | $120,847 | 0 | 1 |
| A multicenter, open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-029 or Part A of INS011-15-054 | $119,180 | 0 | 4 |
| Preliminary Study of Prophylactic Fentanyl Sublingual Spray (FSS) for Exercise-Induced Breakthrough Dyspnea | $115,500 | 0 | 2 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome | $106,442 | 0 | 28 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders | $78,023 | 0 | 133 |
| A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients with Advanced Cancer | $76,865 | 0 | 1 |
| A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailability Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intramuscular Injection in Healthy Volunteers | $63,835 | 0 | 2 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome | $57,698 | 0 | 16 |
| Open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral solution as an adjunctive treatment for pediatric and adult subjects with a treatment-resistant seizure disorder | $43,602 | 0 | 4 |
| A Pivotal, Phase 1, Open-Label, Randomized, Crossover, Single-Dose, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray (6.5 mg/1.63 mg) and Suboxone Sublingual Film (12 mg/3 mg) in Healthy Volunteers under Fasted Conditions | $43,535 | 0 | 1 |
| An Expanded Access Program (EAP) to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-030 | $25,954 | 0 | 4 |
| A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailibility Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intramuscular and Intraveneous Injection in Healthy Volunteers | $20,453 | 0 | 3 |
| A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailibility Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intramuscular Injection in Healthy Volunteers | $20,453 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Steven Wong, Md, MD | Hematology & Oncology | Santa Monica, CA | $188,568 | $0 |
| Dr. Andrew Putnam, Md, MD | Hospice and Palliative Medicine | New Haven, CT | $136,788 | $0 |
| Dr. Khaleel Ashraf, M.d, M.D | Hematology & Oncology | Birmingham, AL | $113,993 | $0 |
| Dr. Leonard Farber, M.d, M.D | Radiation Oncology | Fullerton, CA | $102,093 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $91,658 | $0 |
| Dr. Joseph Pergolizzi, M.d, M.D | Anesthesiology | Naples, FL | $81,280 | $0 |
| Boris Krivitsky, Do, DO | Internal Medicine | Charlotte, NC | $79,694 | $0 |
| Randall Scharlach, Md, MD | Radiation Oncology | Woodland Hills, CA | $75,213 | $0 |
| Dr. Henry Zaleski, M.d, M.D | Specialist | Houston, TX | $74,775 | $0 |
| Dr. Brian Lawenda, M.d, M.D | Radiation Oncology | Venice, FL | $71,697 | $0 |
| Dr. Ashish Udhrain, M.d, M.D | Internal Medicine | Metairie, LA | $69,610 | $0 |
| Dr. Vijay Gunuganti, M.d, M.D | Medical Oncology | San Antonio, TX | $63,329 | $0 |
| Dwight Fitch, Md, MD | Radiation Oncology | Bradenton, FL | $54,618 | $0 |
| Dr. Lang Liebman, M.d, M.D | Radiation Oncology | Richmond, VA | $44,093 | $0 |
| Dr. Daniel Bennett, M.d, Dabpm, M.D, DABPM | Interventional Pain Medicine | Minot, ND | $43,553 | $0 |
| Mr. Irfan Jawed, Md, MD | Medical Oncology | Houston, TX | $43,060 | $0 |
| Randy Calegari, Md, MD | Internal Medicine | Las Vegas, NV | $38,846 | $0 |
| Gladstone Mcdowell, M.d, M.D | Pain Medicine | Columbus, OH | $36,922 | $0 |
| Dr. Jeffrey Kesten, Md, MD | Physical Medicine & Rehabilitation | Las Vegas, NV | $36,653 | $0 |
| Anderson Bauer, M.d, M.D | Radiation Oncology | Marshfield, WI | $34,190 | $0 |
| Robert Liebross, Md, MD | Radiation Oncology | Indianapolis, IN | $32,850 | $0 |
| Dr. Ijaz Mahmood, M.d, M.D | Hematology & Oncology | Elizabethtown, KY | $32,591 | $0 |
| Dr. Nicola Jabbour, M.d, M.D | Hematology & Oncology | Lexington, KY | $27,728 | $0 |
| Unknown Provider | — | — | $25,659 | $0 |
| Dr. Edward Michna, Md, MD | Anesthesiology | Boston, MA | $25,400 | $0 |
Ad
Top Products
- Buprenorphine $4.2M
- Cannabidiol $2.6M
Associated Products (10)
- Buprenorphine $7.6M
- Cannabidiol $2.6M
- SUBSYS $1.6M
- subsys $1.0M
- SYNDROS $796,991
- Buprenorphine-Naloxone $355,209
- Dronabinol $340,508
- Subsys $63,859
- Cannabidiol Oral Solution (OS) $48,606
- Dronabinol (OS) $17,539
Payment Categories
- Food & Beverage $334,136
- Consulting $867,248
- Travel & Lodging $269,546
- Research $10.3M
About INSYS Therapeutics Inc
INSYS Therapeutics Inc has made $13.0M in payments to 6,122 healthcare providers, recorded across 18,902 transactions in the CMS Open Payments database. In 2018, the company paid $3.7M. The top product by payment volume is Buprenorphine ($4.2M).
Payments were distributed across 118 medical specialties. The top specialty by payment amount is Hematology & Oncology ($522,375 to 975 doctors).
Payment categories include: Food & Beverage ($334,136), Consulting ($867,248), Research ($10.3M), Travel & Lodging ($269,546).
INSYS Therapeutics Inc is associated with 10 products in the CMS Open Payments database, including Buprenorphine, Cannabidiol, and SUBSYS.